The Long-term Effects of Metformin on Patients With Type 2 Diabetic Kidney Disease.

Soie KwonYong Chul KimJae Yoon ParkJeonghwan LeeJung Nam AnClara Tammy KimSohee OhSeokwoo ParkDong Ki KimYun Kyu OhYon Su KimChun Soo LimJung Pyo Lee

Published in: Diabetes care (2020)

In the present retrospective study, metformin usage in advanced chronic kidney disease (CKD) patients, especially those with CKD 3B, decreased the risk of all-cause mortality and incident ESRD. Additionally, metformin did not increase the risk of lactic acidosis. However, considering the remaining biases even after PSM, further randomized controlled trials are needed to change real-world practice.

Keyphrases

chronic kidney disease
end stage renal disease
peritoneal dialysis
randomized controlled trial
type diabetes
primary care
cardiovascular disease
newly diagnosed
ejection fraction
systematic review
clinical trial
quality improvement
study protocol